GWP
TNXP icon

Gen-Wealth Partners’s Tonix Pharmaceuticals TNXP Stock Holding History

Gen-Wealth Partners’s Portfolio TNXP Stock Details TNXP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$7.33K Hold
533
– – ﹤0.01% 566
2025
Q4 		$8.32K Hold
533
– – ﹤0.01% 532
2025
Q3 		$12.9K Buy
+533
New +$19.8K ﹤0.01% 499

Other funds holding TNXP

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
JHC
Jones Hill Capital New York $466M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Gen-Wealth Partners's TNXP Position: Q1 2026 in Review

Gen-Wealth Partners held its Tonix Pharmaceuticals (TNXP) position steady in Q1 2026 at 533 shares worth $7.33K. The position accounts for ﹤0.01% of the portfolio, ranked #566.

Gen-Wealth Partners first reported a position in TNXP in Q3 2025 and has held it in 3 quarters since. The position peaked at $12.9K in Q3 2025. 81 funds tracked by Wall St. Rank hold TNXP as of Q1 2026.

  • Gen-Wealth Partners held 533 shares of Tonix Pharmaceuticals worth $7.33K as of Q1 2026.
  • Gen-Wealth Partners left its Tonix Pharmaceuticals share count unchanged in Q1 2026.
  • Tonix Pharmaceuticals made up ﹤0.01% of Gen-Wealth Partners's portfolio in Q1 2026, its #566 holding.
  • Gen-Wealth Partners first reported a position in Tonix Pharmaceuticals in Q3 2025 and has held it in 3 quarters since.
  • Gen-Wealth Partners's Tonix Pharmaceuticals position peaked at $12.9K in Q3 2025.
  • 81 funds tracked by Wall St. Rank held Tonix Pharmaceuticals as of Q1 2026.

Based on Gen-Wealth Partners's 13F filing for Q1 2026, filed 8 May 2026.